Video
Video
08/21/2026
Brittany Albright, MD, MPH
In this video, Brittany Albright, MD, discusses why primary care clinicians are often the first line of defense in recognizing and treating anxiety disorders. She reviews practical strategies for screening,...
08/21/2026
Research Summary
Research Summary
08/06/2026
Ashton L. Stahl
A US prescription claims study evaluated uptake and 2-year persistence among users of long-acting injectable cabotegravir for HIV PrEP.
08/06/2026
Research Summary
Research Summary
08/06/2026
Anthony Calabro, MA
In the double-blind EPCAT III RCT, aspirin alone was noninferior to 5 days of rivaroxaban followed by aspirin for preventing symptomatic VTE after total hip or knee arthroplasty, with no clinically relevant...
08/06/2026
Research Summary
Research Summary
08/05/2026
Anthony Calabro, MA
A systematic review and pooled meta-analysis of 17 RCTs involving 5,500 adolescents and adults found little evidence that very low nicotine content cigarettes increased cigarette consumption or carbon...
08/05/2026
FDA Approval
FDA Approval
07/24/2026
Anthony Calabro, MA
The FDA approval introduces a nonprescription fixed-dose combination of 2 widely used analgesics for temporary relief of common minor aches and pains in adults and children aged 12 years or older.
07/24/2026
Research Summary
Research Summary
07/08/2026
Anthony Calabro, MA
Improving TDF-FTC uptake among US young men who have sex with men on HIV PrEP could yield substantial 10-year value, while a hypothetical study eliminating adverse event uncertainty would not change the...
07/08/2026
Research Summary
Research Summary
07/01/2026
Anthony Calabro, MA
In two phase 3, double-blind, placebo-controlled trials of adults with noncirrhotic chronic hepatitis B virus infection receiving stable nucleoside or nucleotide analog therapy, 24 weeks of bepirovirsen...
07/01/2026
FDA Approval
FDA Approval
06/30/2026
Anthony Calabro, MA
The FDA approved tebipenem pivoxil (Utebzi) for adults with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral treatment options.
06/30/2026
FDA Approval
FDA Approval
06/25/2026
Anthony Calabro, MA
The FDA approved expanded adjuvant therapy options for adults with renal cell carcinoma with a clear cell component who are at intermediate-high or high risk of recurrence after nephrectomy, with or without...
06/25/2026
Disease State Pillar
Disease State Pillar
06/25/2026
Anthony Calabro, MA
IgG4-related disease is unlikely to be the first diagnosis suspected in primary care, but PCPs may be the first clinicians to recognize the atypical, recurrent, mass-like, or multiorgan patterns that should...
06/25/2026